EFSA says the safety of isolated CBD could not be established
Safety of cannabidiol isolated from Cannabis sativa L. as a novel food pursuant to Regulation (EU) 2015/2283.
AI Summary
This EFSA safety assessment examined whether CBD isolated from Cannabis sativa L. could be considered safe as a novel food under European Union regulations. The proposed product contained ≥98% w/w CBD, was made through extraction and purification steps, and was intended for use in food supplements at a maximum intake of 60 mg/day for adults, excluding pregnant and lactating women. This was a regulatory risk assessment based on submitted evidence, not a clinical trial testing health benefits.
During its review, the panel identified missing information about the product’s identity, manufacturing process, composition, specifications, genotoxicity, reproductive and developmental toxicity, and human data. The applicant did not provide the requested additional information. Based on the available evidence, EFSA concluded that the safety of this CBD novel food could not be established. This abstract-based summary cannot determine whether the product is harmful or safe in practice; it reports that the available data were insufficient for a safety conclusion.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.